MedTrace Logo

Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

NCT02878564 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2016-10-27

No results posted yet for this study

Summary

The aim of this study is to assess the impact of Schistosoma mansoni infection and its treatment on genital immunology and HIV susceptibility in Ugandan women.

Conditions

  • Schistosomiasis Mansoni
  • HIV

Interventions

DRUG

Praziquantel

40 mg/kg, PO (orally administered tablets)

Sponsors & Collaborators

  • UVRI-IAVI HIV Vaccine Program, Uganda

    collaborator UNKNOWN

  • University of Toronto

    lead OTHER

Principal Investigators

  • Rupert Kaul, MD/PhD · University of Toronto

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878564 on ClinicalTrials.gov